Venture Challenge winners awarded in international competition

It’s all about cryogenic electron microscopy and an unexpected victory for the successful research group at Uppsala University. After six intensive months, the team stands as the overall winner in a major international competition—a win that not only proves their method works, but also opens up new possibilities in protein analysis. Meet Gabriel Ducrocq, a researcher affiliated with Sebastian Westenhoff’s group at Uppsala University.

Gabriel Ducrocq

A competition of this caliber spans a long period of time—in this case, a full six months. Overcoming such a major challenge requires a team with cutting-edge expertise and experience across several different fields. Yet, that is not enough. In addition, and perhaps most crucially, it requires the ability to collaborate—something the research group led by Gabriel Ducrocq did better than anyone else.

 

A well-rounded team was crucial

“Our team has developed a completely new workflow that changes the possibilities for what can be done. We started with an idea and boosted it with biochemical knowledge. That kind of approach requires effort, time, and determination. The result? Fantastic,” says Gabriel Ducrocq, PhD.

Winning the CAHRA Challenge 2026, conformational heterogeneity category, has meant a great deal to the team. It has brought great publicity, new contacts, and increased interest from more people wanting to use the method in their work.

“What we have developed is a brand-new machine learning workflow for protein analysis. Winning is fantastic fun and a great validation that what we can offer is a method that works.”

 

New and improved analyses

The advantage of the newly updated, award-winning workflow is that it offers new opportunities to perform better analyses, as it delivers information that increases understanding of both how a protein moves and which molecules can target a protein. Already, the team is gearing up to present the method to interested researchers when SciLifeLab organizes a workshop in cryo-EM.

Med bilder och information om målproteiner kan läkemedelskandidater anpassas.

With images and information about target proteins, drug candidates can be tailored.

 

A great opportunity for researchers to test the method

“It will be interesting to hear more about what the researchers interested in our technology are working on and what questions they want answered. During the workshop, we will help install the system and assist participants in using it. For us, it is a great opportunity to evaluate the system and, not least, learn more about researchers’ needs so we can refine and expand the system.”

Continued development work For the team behind the system, there are more challenges to tackle. Among other things, this involves reaching out to more stakeholders who want to test the workflow—not least Big Pharma, the major players in the field. It also involves continuing to develop the system, which comes with costs. Working to raise more capital is therefore another important part of the road ahead.

“Our sights are set both on finding more investors and, in the near future, signing our first paying customer to the company. Ideally, this would be one of the major players in the industry that acts as an important influencer in this field.”

The collaboration with UU Invest has been, and continues to be, an important part of the company’s progress moving forward.

 

Collaboration with UU Invest provides key advantages going forward

“We are researchers at heart, so the collaboration with UU Invest means a lot to us. We feel strong support and truly appreciate the partnership we have together. It means a great deal and brings vital knowledge into the project.”

Another initiative that has meant a lot to the team behind Cryosphere and their development work in cryogenic electron microscopy is their participation in Venture Challenge—an opportunity that Gabriel gladly recommends other researchers explore if they also want to take their research further and turn it into useful products or services.

Read more about Gabriel Ducrocq and his team here: https://gabriel-ducrocq.github.io/cryosphere.github.io/

If you would like to know more about Venture Challenge, please contact Mateo Santurio, UU Invest.

Aktuellt

Visa:

Jubileumsskrift UU Invest 30 år 2025

Jubileumsskrift

30 år av framgångsrika startups från universitetet. UU Invest är Uppsala universitets investeringsbolag med uppdrag att investera i forsk-
ningsbaserade bolag. Sedan starten 1995 har vi investerat i mer än 115 bolag – företag som idag återfinns inom olika branscher där de bidrar till samhällsnytta och tillväxt.
I år firar vi 30 år av aktivt ägande och konstaterar att många av våra portföljbolag utvecklats
till starka aktörer på nationella och internationella marknader.

Jacinto Sá, Professor vid Institutionen för kemi – Ångström

More pleasant indoor climate with new energy-efficient technology

Development is progressing rapidly at the new company Duck Technologies. If everything goes according to plan, the hope is that the company’s first product will be ready for the market within two years. What remains is to scale up and package a new opportunity to save energy by reducing heat intake through, among other things, windows in buildings and cars.

me

International research collaboration brings hope for glioblastoma treatment

Mesenkia Therapeutics, backed by UU Invest, is developing a groundbreaking treatment for glioblastoma, the most aggressive brain cancer. The startup is preparing clinical trials to create a drug aimed at extending patients’ lives.

vinnarna av venturechallenge2024

The duo behind SoundSim360 – Winners of VentureChallenge 2024

SoundSim360, developed by Professor Ken Mattsson and Dr. Gustav Eriksson, is an advanced sound simulation tool for precise sound level predictions that handles complex acoustics, including low-frequency sounds for wind turbines, arenas, and home theater systems.

Collaboration graphic visual. Teamwork graphics.

From Research to Business – Collaboration between UU Innovation and UU Invest shorten your time to market

UU Invest hosts your project so that you can establish necessary agreements with collaborative partners, hire key personnel to investigate or develop the concept, and also assist ‘hands on’ in negotiations and strategic work.

Ida-Maria Sintorn portrait

SimSearch – New powerful tool in the work with biological microscope images

Ida-Maria Sintorn, along with her colleagues in the SimSearch project, is developing new technology for image processing of microscopic images. The focus is to make it easier, faster, and safer for researchers to extract relevant information from large amounts of data while retaining control over their own data.

CEO of HyEnGen Oscar Verho

HyEnGen – Pioneering Research for Sustainable Energy Production

Oscar Verho and his research network are focused on creating more efficient ways to produce fuels from water. The path involves advanced interdisciplinary development and a sustainable, efficient electrode with the potential to make green hydrogen production more cost-effective.

Matteo, en av Paperhives grundare.

AI accelerates evidence-based clinical decisions

PapersHive is one of UU Invest’s 55 portfolio companies. With an AI-based search technology, the company collects information from all medical databases in one place. This saves both time and money for pharmaceutical companies, CROs and medical technology companies.

Graphic footage with text that describes that venturechallenge 2023 is now closed.

Applications for VentureChallenge 2023 are now closed

Applications for VentureChallenge 2023 are now closed. A new call for applications will open again in the first quarter of 2024.

Tv. Gunilla Lundmark
Verkställande direktör UU Invest

Th. Malin Graffner Nordberg
Chef vid Uppsala universitet Innovation (UU Innovation)

Foto Mikael Wallerstedt

Successful collaboration delivers results

Meet Gunilla Lundmark, CEO of UU Invest, and Malin Graffner Nordberg, Head of UU Innovation. With different roles and expertise, they work towards the same overall goal – to contribute to Uppsala University’s efforts to take research forward and utilise knowledge in society.

Linus Bosaeus, VD för Rarity Bioscience

Precisionsdiagnostik i fokus för Rarity Bioscience

Ulf Landegren och hans forskningsgrupp ligger bakom banbrytande forskning som lett till nya innovationer som framgångsrikt förvaltats och utvecklats i en rad olika bolag. Rarity Bioscience med vd Linus Bosaeus är ett av de senaste i raden.